Recommendation Edges Pomalyst Closer To Japan Launch
This article was originally published in PharmAsia News
Japan has issued approval recommendations and other regulatory decisions for a batch of drugs including Celgene's myeloma therapy Pomalyst, which now looks set to be approved and possibly launched in the country within the next few months.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.